Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 582-588

  Xiao, Hui ^a   Wang, Juan ^a   Liu, Yanan ^a   Li, Li ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

C Kit; Epidermal growth factor receptor; Lung cancer; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLEURA; PROTEIN EXPRESSION; SMOKING; TUMOR VOLUME;

EID: 84902348051     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2173     Document Type: Article

References (22)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. American Thoracic Society; Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416, 2005.
3. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998.
4. Thiel G, Ekici M and Rössler OG: Regulation of cellular proliferation, differentiation and cell death by activated Raf. Cell Commun Signal 7: 8, 2009.
5. Mirsadraee M, Oswal D, Alizade Y, et al: The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol 4: 128-134, 2012.
6. Lei B, Liu S, Qi W, et al: PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression. Histopathology 63: 696-703, 2013.
7. Erler BS, Presby MM, Finch M, et al: CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma. Tumour Biol 32: 107-111, 2011.
8. Mohammad T, Garratt J, Torlakovic E, Gilks B and Churg A: Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice. Am J Surg Pathol 36: 1503-1508, 2012.
9. Cheng D, Kong H and Li Y: Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer. Biomarkers 18: 386-390, 2013.
10. Chatterjee S, Heukamp LC, Siobal M, et al: Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 123: 1732-1740, 2013.
11. Yang Y, Li J, Mao S and Zhu H: Comparison of immunohistology using pan-CK and EMA in the diagnosis of lymph node metastasis of gastric cancer, particularly micrometastasis and isolated tumor cells. Oncol Lett 5: 768-772, 2013.
12. Kanapathy Pillai SK, Tay A, Nair S and Leong CO: Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol 12: 18, 2012.
13. Al-Dubai SA, Qureshi AM, Saif-Ali R, Ganasegeran K, Alwan MR and Hadi JI: Awareness and knowledge of breast cancer and mammography among a group of Malaysian women in Shah Alam. Asian Pac J Cancer Prev 12: 2531-2538, 2011.
14. Casali C, Stefani A, Rossi G, et al: The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 77: 247-253, 2004.
15. Boldrini L, Ursino S, Gisfredi S, et al: Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res 10: 4101-4108, 2004.
16. López-Martin A, Ballestín C, Garcia-Carbonero R, et al: Prognostic value of KIT expression in small cell lung cancer. Lung Cancer 56: 405-413, 2007.
17. Yoo J, Kim CH, Song SH, et al: Expression of c-kit and p53 in non-small cell lung cancers. Cancer Res Treat 36: 167-172, 2004.
18. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353: 133-144, 2005.
19. Hirsch FR, Herbst RS, Olsen C, et al: Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26: 3351-3357, 2008.
20. Park EA, Lee HJ, Kim YT, et al: EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology. Lung Cancer 64: 179-186, 2009.
21. Dy GK, Miller AA, Mandrekar SJ, et al: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 16: 1811-1816, 2005.
22. Schneider BJ, Kalemkerian GP, Ramnath N, et al: Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer 11: 223-227, 2010.